

Special Issue

Personalized Treatment of Neurological Diseases

Message from the Guest Editors

Individualized treatment of patients with epilepsy: this can include a comprehensive review of all data in the literature around the individualized holistic approach of the patient in relation to comorbidities, age, sex, side effects of drugs, EEG, imaging, gene testing, and other relevant factors. Additionally, I would like to invite authors to submit articles on the individualized treatment of specific subcategories of epilepsy, such as autoimmune epilepsy. Personalized treatment for patients with dementia: this can include articles that focus on the latest advancements in personalized treatment for patients with dementia, including pharmacological and non-pharmacological interventions. Personalized approach for patients with dementia through artificial intelligence: this can include articles that focus on the application of quantitative EEG in the diagnosis of patients with dementia and how artificial intelligence can be used to personalize treatment approaches for patients with dementia.

Guest Editors

Dr. Theodora Afrantou

Dr. Panagiotis Ioannidis

Dr. Katerina D. Tzimourta

Deadline for manuscript submissions

25 January 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/205488

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).